Alzheimer’s disease

Byaibio

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive dysfunction, amyloid-β plaques, neurofibrillary tangles, and cholinergic deficits, and it is a major focus of biomarker-guided clinical research. Biomarkers are widely used across active disease-targeted therapeutic trials, including studies of biomarker of alzheimers disease, tau PET trajectories, and multimodal risk assessment, reflecting the field’s shift toward earlier detection and stratification. Mechanistically, the disease is linked to amyloid-β generation via bace1, tau pathology, pathogenic post-translational modifications, mitochondrial dysfunction, and dysregulated mitochondria-organelle interactions, with additional genetic modifiers such as apoe4, apoe, and app. Therapeutic development spans anti-amyloid monoclonal antibodies, BACE1 inhibitors, tau aggregation inhibition, CRISPR-based APOE4 correction, stem-cell and nanobody delivery strategies, and metabolic or anti-inflammatory approaches. Recent advances include phase 3 testing of hydromethylthionine mesylate and oral semaglutide in early symptomatic disease, plus mechanistic studies implicating microglial idh1, BNIP3-dependent mitophagy, ferroptosis, and cerebral amyloidosis progression. Overall, Alzheimer’s disease remains a heterogeneous disorder with multiple molecular subtypes and a broad pipeline of disease-modifying and preventive interventions.

Biomarkers, risk, and disease stratification

  • Biomarkers were widely used across active Alzheimer’s disease disease-targeted therapeutic trials, underscoring their central role in trial enrollment and monitoring. (PMID:41716297)
  • A 2026 Current Alzheimer Research study (PMID:41879435) described risk assessment models and biomarker screening using bioinformatics and machine learning algorithms. (PMID:41879435)
  • The disease spectrum was analyzed through multimodal biomarker integration and adaptive clinical translation, highlighting molecular subtypes. (PMID:41975594)
  • The FINGER randomized trial linked an Alzheimer genetic risk score to cognition, showing how genetic and clinical risk are being integrated. (PMID:40747850)
  • Exposome associations with brain aging were evaluated in a multinational cohort that included Alzheimer’s disease participants. (PMID:41933172)

Amyloid, tau, and core pathophysiology

  • Alzheimer’s disease pathology includes amyloid-β plaques, tau deposition, and pathogenic protein post-translational modifications. (PMID:41838033)
  • Amyloid-β accumulation and cerebral amyloidosis were discussed alongside progressive mitochondrial dysfunction as part of disease progression. (PMID:41637762)
  • 3-Deoxyanthocyanidins inhibited β-amyloid aggregation, toxicity, and mitochondrial dysfunction in cellular and simulation models. (PMID:41633420)
  • A systematic review of quantitative systems pharmacology models focused on anti-amyloid treatments for Alzheimer’s disease. (PMID:41782463)
  • BACE1 was highlighted as a key therapeutic target because it drives amyloid-β peptide generation. (PMID:41838033)

Genetics, APOE, and molecular vulnerability

  • Sex- and APOE genotype-specific regional white matter vulnerability was reported, emphasizing genotype-dependent disease heterogeneity. (PMID:41708549)
  • APOE4 correction strategies and CRISPR-based therapeutics were discussed as emerging precision approaches. (PMID:41812941)
  • APP mutations were used in AD-relevant human and rodent models to study disease mechanisms. (PMID:41812941)
  • Vasculature-specific mechanisms were correlated with APOE4 genetic risk, linking genotype to regional vulnerability. (PMID:41708549)
  • Lithium deficiency was proposed as a possible contributor to Alzheimer disease pathogenesis. (PMID:41770546)

Mitochondria, mitophagy, and cell-death pathways

  • Mitochondrial dysfunction was repeatedly identified as a central driver, including dysfunction of mitochondria-associated ER membranes causing calcium overload and oxidative stress. (PMID:41707907)
  • The interplay between mitophagy and ferroptosis was reviewed as a therapeutic axis in Alzheimer’s disease. (PMID:41823685)
  • Ajugol improved mitochondrial dysfunction and cognitive decline via BNIP3-dependent mitophagy. (PMID:41819485)
  • Kinsenoside restored microglial immune-metabolic homeostasis by targeting idh1, with therapeutic benefit in Alzheimer’s disease. (PMID:41980178)
  • VBIT-4 protected Alzheimer’s disease mouse models against apoptosis, pyroptosis, ferroptosis, and associated pathologies. (PMID:41964801)

Therapeutics, prevention, and clinical trials

  • Anti-amyloid monoclonal antibodies and broader antibody therapies were described as disease-modifying approaches that can slow cognitive decline in mildly impaired patients. (PMID:41722593)
  • Oral semaglutide was tested in two phase 3 randomized placebo-controlled trials in early-stage symptomatic Alzheimer’s disease. (PMID:41865758)
  • Hydromethylthionine mesylate was evaluated in a phase 3 trial in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease. (PMID:41570392)
  • The ALPS trial aims to improve cognition and Alzheimer’s pathophysiology through slow-wave sleep. (PMID:41715219)
  • CRISPR/Cas9, stem-cell therapy enhancement, and nanobody-based delivery were all discussed as next-generation therapeutic platforms. (PMID:41926312)